<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400905</url>
  </required_header>
  <id_info>
    <org_study_id>CID-100</org_study_id>
    <nct_id>NCT02400905</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System</brief_title>
  <acronym>MIMICS-2</acronym>
  <official_title>MIMICS-2: Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System in the Femoropopliteal Arteries of Patients With Symptomatic Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veryan Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinLogix. LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale Cardiovascular Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Veryan Medical Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that the BioMimics 3D Stent System meets the performance goals defined by VIVA
      Physicians, Inc. for the safety and effectiveness of Nitinol stents used in the treatment of
      symptomatic disease of the femoropopliteal artery. It is a prospective, single-arm,
      multicenter clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BioMimics 3D stent is intended to improve luminal diameter in the treatment of
      symptomatic de-novo, obstructive or occlusive lesions in native femoropopliteal arteries with
      reference vessel diameters ranging from 4.0 - 6.0 mm. Subjects with symptomatic
      atherosclerotic disease of the femoropopliteal artery who comply with all study eligibility
      criteria may be considered for enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2015</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">November 8, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint (Freedom From a Composite of Major Adverse Events (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from a composite of major adverse events (MAE) comprising death, any major amputation performed on the target limb or clinically-driven target lesion revascularization (TLR) through 30 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint (Primary Stent Patency Rate)</measure>
    <time_frame>12 months</time_frame>
    <description>Primary stent patency rate at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety (Overall MAE Rate at 30 Days)</measure>
    <time_frame>30 Days</time_frame>
    <description>Contribution of individual MAE rates for death, major amputation performed on the target limb and clinically-driven target lesion revascularization to the overall MAE rate at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Term Safety (Overall MAE Rate at Month 12)</measure>
    <time_frame>12 months</time_frame>
    <description>Overall MAE rate at Month 12 and contribution of individual event rates to the overall MAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Term Safety (Overall Rate and Incidence of Type of Serious Adverse Events)</measure>
    <time_frame>36 Months</time_frame>
    <description>Overall rate and incidence of type of serious adverse events from Day 0 through completion of Study follow-up at Month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Procedural (at end of index procedure)</time_frame>
    <description>Percentage of subjects in which a final result of ≤50% residual diameter stenosis (in-stent) was achieved at index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Stent Patency</measure>
    <time_frame>Months 12 &amp; 24</time_frame>
    <description>Determined at Months-12 and 24 using values of: PSVR &gt;2.0, &gt;2.4; &gt;2.5; and &gt;3.5, each to indicate loss of patency on duplex ultrasound or where angiography reveals &gt;50% diameter stenosis or where the subject undergoes clinically-driven TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome (Rutherford Clinical Category)</measure>
    <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of Rutherford Clinical Category measured at Baseline, Day 30, Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome (Six-Minute Walk Test)</measure>
    <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of measured at Baseline, Day 30, Months 12 and 24 (subgroup of US investigational sites only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome (Ankle Brachial Index (ABI) Measurement)</measure>
    <time_frame>Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of the ankle brachial index (ABI) measurement at Baseline, within 30 days after index procedure, then at Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome (Walking Impairment Questionnaire)</measure>
    <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of the Walking Impairment Questionnaire at Baseline, within 30 days after index procedure, then at Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Integrity (Measured as Freedom From Stent Fracture)</measure>
    <time_frame>Months 12, 24 &amp; 36</time_frame>
    <description>Stent integrity measured as freedom from stent fracture.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>BioMimics 3D Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioMimics 3D Stent System</intervention_name>
    <description>Femoropopliteal stenting</description>
    <arm_group_label>BioMimics 3D Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic peripheral arterial disease (PAD) of the lower extremities requiring
             intervention to relieve de novo obstruction or occlusion of the native femoropopliteal
             artery.

          -  PAD classified as Rutherford clinical category 2, 3 or 4.

          -  Resting ankle-brachial index (ABI) of ≤0.90 (or ≤0.75 after exercise of the target
             limb) or angiographic or DUS evidence of &gt;/= 60%.

          -  Single or multiple stenotic or occlusive lesions within the native femoropopliteal
             artery (&quot;target lesions&quot;) that can be crossed with a guidewire and fully dilated.

          -  Single or multiple target lesions must be covered by a single stent or two overlapping
             stents.

          -  Target lesion(s) eligible for treatment at least 1 cm distal to the origin of the deep
             femoral artery and at least 3 cm above the bottom of the femur.

          -  Target lesion(s) reference vessel diameter is between 4.0 mm and 6.0 mm.

          -  Single or multiple target lesions measure ≥40 mm to ≤140 mm in overall length, with
             ≥60% diameter stenosis by operator's visual estimate.

          -  Patent popliteal artery (no stenosis ≥50%) distal to the treated segment.

          -  At least one patent infrapopliteal vessel (&lt;50% stenosis) with run-off to the ankle.

        Exclusion Criteria:

          -  Iliac stent in target limb that has required re-intervention within 12 months prior to
             index.

          -  Target vessel that has been treated with bypass surgery.

          -  PAD classified as Rutherford clinical category 0, 1, 5 or 6.

          -  Known coagulopathy or has bleeding diatheses, thrombocytopenia with platelet count
             less than 100,000/microliter or INR &gt;1.8.

          -  Stroke diagnosis within 3 months prior to enrollment.

          -  History of unstable angina or myocardial infarction within 60 days prior to
             enrollment.

          -  Thrombolysis within 72 hours prior to the index procedure.

          -  Acute or chronic renal disease (e.g., as measured by a serum creatinine of &gt;2.5 mg/dL
             or &gt;220 umol/L), or on peritoneal or hemodialysis.

          -  Significant disease or obstruction (≥50%) of the inflow tract that has not been
             successfully treated at the time of the index procedure (success measured as ≤30%
             residual stenosis, without complication).

          -  No patent (≥50% stenosis) outflow vessel providing run-off to the ankle.

          -  Target lesion(s) requires percutaneous interventional treatment, beyond standard
             balloon angioplasty alone, prior to placement of the study stent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M. Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Heart Institute / Abbott Northwestern Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Zeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herz-Zentrum University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masato Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toho University Ohashi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brookwood Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Mobile</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradenton Cardiology Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediQuest Research Group/ Munroe Regional Medical Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Vascular</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings Daughters Medical Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endovascular Technologies / Grace Research</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Outpatient Vascular Institute</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital &amp; Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Vascular Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart &amp; Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Harrisburg</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berks Cardiologists</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Heart</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kore Cardiovascular Research</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Specialist of TX / North Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grace Research</name>
      <address>
        <city>Huntsville</city>
        <state>Texas</state>
        <zip>77340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Research Institute/Guadalupe Regional Medical Center</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinen-Hospital</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Herzzentrum Freiburg-Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Flensburg</name>
      <address>
        <city>Flensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westküstenklinikum Heide</name>
      <address>
        <city>Heide</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AoR Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bonifatius Hospital</name>
      <address>
        <city>Lingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasukabe Chuo General Hospital</name>
      <address>
        <city>Kasukabe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morinomiya Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omihachiman Community Medical Center</name>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <results_first_submitted>November 5, 2018</results_first_submitted>
  <results_first_submitted_qc>December 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2019</results_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>PVD</keyword>
  <keyword>SFA stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02400905/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02400905/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BioMimics 3D Stent</title>
          <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12-month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject refused visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BioMimics 3D Stent</title>
          <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="271"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.4" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint (Freedom From a Composite of Major Adverse Events (MAE)</title>
        <description>Freedom from a composite of major adverse events (MAE) comprising death, any major amputation performed on the target limb or clinically-driven target lesion revascularization (TLR) through 30 days.</description>
        <time_frame>30 days</time_frame>
        <population>Subjects with available 30 day follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint (Freedom From a Composite of Major Adverse Events (MAE)</title>
          <description>Freedom from a composite of major adverse events (MAE) comprising death, any major amputation performed on the target limb or clinically-driven target lesion revascularization (TLR) through 30 days.</description>
          <population>Subjects with available 30 day follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Effectiveness Endpoint (Primary Stent Patency Rate)</title>
        <description>Primary stent patency rate at 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>Subjects were included in analysis population if they had imaging data qualifying as a 12m visit and/or subjects without imaging data who experienced a CDTLR through 12 months. Additionally, if a subject is missing stent patency status at the 12m window but found to be patent at a later out-of-window date, subject was considered patent at 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Effectiveness Endpoint (Primary Stent Patency Rate)</title>
          <description>Primary stent patency rate at 12 months.</description>
          <population>Subjects were included in analysis population if they had imaging data qualifying as a 12m visit and/or subjects without imaging data who experienced a CDTLR through 12 months. Additionally, if a subject is missing stent patency status at the 12m window but found to be patent at a later out-of-window date, subject was considered patent at 12 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety (Overall MAE Rate at 30 Days)</title>
        <description>Contribution of individual MAE rates for death, major amputation performed on the target limb and clinically-driven target lesion revascularization to the overall MAE rate at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Subjects with available 30 day follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Safety (Overall MAE Rate at 30 Days)</title>
          <description>Contribution of individual MAE rates for death, major amputation performed on the target limb and clinically-driven target lesion revascularization to the overall MAE rate at 30 days.</description>
          <population>Subjects with available 30 day follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Freedom from Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from Major Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from CD-TLR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Safety (Overall MAE Rate at Month 12)</title>
        <description>Overall MAE rate at Month 12 and contribution of individual event rates to the overall MAE.</description>
        <time_frame>12 months</time_frame>
        <population>Subjects are included in the analysis population if (i) they have sufficient follow-up (at least 12 months less 30 days), or (ii) they have had the event of interest (each event is considered separately).</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Long Term Safety (Overall MAE Rate at Month 12)</title>
          <description>Overall MAE rate at Month 12 and contribution of individual event rates to the overall MAE.</description>
          <population>Subjects are included in the analysis population if (i) they have sufficient follow-up (at least 12 months less 30 days), or (ii) they have had the event of interest (each event is considered separately).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Freedom from MAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from Death</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from Major Amputation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from CD-TLR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Safety (Overall Rate and Incidence of Type of Serious Adverse Events)</title>
        <description>Overall rate and incidence of type of serious adverse events from Day 0 through completion of Study follow-up at Month 36.</description>
        <time_frame>36 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success</title>
        <description>Percentage of subjects in which a final result of ≤50% residual diameter stenosis (in-stent) was achieved at index procedure</description>
        <time_frame>Procedural (at end of index procedure)</time_frame>
        <population>Subjects with available baseline angiography</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success</title>
          <description>Percentage of subjects in which a final result of ≤50% residual diameter stenosis (in-stent) was achieved at index procedure</description>
          <population>Subjects with available baseline angiography</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Stent Patency</title>
        <description>Determined at Months-12 and 24 using values of: PSVR &gt;2.0, &gt;2.4; &gt;2.5; and &gt;3.5, each to indicate loss of patency on duplex ultrasound or where angiography reveals &gt;50% diameter stenosis or where the subject undergoes clinically-driven TLR.</description>
        <time_frame>Months 12 &amp; 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome (Rutherford Clinical Category)</title>
        <description>Comparison of Rutherford Clinical Category measured at Baseline, Day 30, Months 12 and 24.</description>
        <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome (Six-Minute Walk Test)</title>
        <description>Comparison of measured at Baseline, Day 30, Months 12 and 24 (subgroup of US investigational sites only).</description>
        <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Outcome (Ankle Brachial Index (ABI) Measurement)</title>
        <description>Comparison of the ankle brachial index (ABI) measurement at Baseline, within 30 days after index procedure, then at Months 12 and 24.</description>
        <time_frame>Day 30, Months 12 &amp; 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Outcome (Walking Impairment Questionnaire)</title>
        <description>Comparison of the Walking Impairment Questionnaire at Baseline, within 30 days after index procedure, then at Months 12 and 24.</description>
        <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Integrity (Measured as Freedom From Stent Fracture)</title>
        <description>Stent integrity measured as freedom from stent fracture.</description>
        <time_frame>Months 12, 24 &amp; 36</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BioMimics 3D Stent</title>
          <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Congestive heart failure (CHF)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-intestinal bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infected peripheral wound</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Urinary tract infection (UTI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusion/thrombus at puncture site</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Vascular access complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Groin hematoma ≥ 5 cm, with or without surgical repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Stroke or other neurological complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure/renal insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Restenosis of treated segment</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Arterial stenosis (non-target)</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Restenosis of treated vessel</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Limb ischemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Abrupt occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Amputation (unplanned, spontaneous)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dissection (≥ Grade C) in target vessel requiring intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Embolization, distal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Total occlusion of the peripheral artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nick Yeo</name_or_title>
      <organization>Veryan Medical</organization>
      <phone>+44 1403 258984</phone>
      <email>nick.yeo@veryanmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

